(3R)-3-[(R)-(3-氯苯基)羟基甲基]-1-哌啶羧酸1,1-二甲基乙基酯 | 942142-74-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: (3R)-3-[(R)-(3-氯苯基)羟基甲基]-1-哌啶羧酸1,1-二甲基乙基酯
• 中文别名: (R)-3-((R)-(3-氯苯基)(羟基)甲基)哌啶-1-甲酸叔丁酯
• 英文名称: (R)-tert-butyl 3-((R)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-[(R)-(3-chlorophenyl)(hydroxy)-methyl]-1-piperidinecarboxylate；tert-butyl (R)-3-((R)-(3-chlorophenyl)(hydroxy)methyl)piperidine-1-carboxylate；1-Piperidinecarboxylic acid, 3-[(R)-(3-chlorophenyl)hydroxymethyl]-, 1,1-dimethylethyl ester, (3R)-；tert-butyl (3R)-3-[(R)-(3-chlorophenyl)-hydroxymethyl]piperidine-1-carboxylate
• CAS: 942142-74-7
• 化学式: C₁₇H₂₄ClNO₃
• 分子量: 325.835
• InChiKey: ADRSZIQSSXPARX-HIFRSBDPSA-N

物化性质

• 沸点：
  432.6±20.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R)-3-[(R)-(3-氯苯基)羟基甲基]-1-哌啶羧酸1,1-二甲基乙基酯 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 sodium azide 、 水 、 sodium hydride 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 35.0h， 生成 (3R)-3-[(R)-(3-氯苯基)[2-[(甲氧羰基)氨基]乙氧基]甲基]-1-哌啶羧酸1,1-二甲基乙基酯
  参考文献：
  名称：

  Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility

  摘要：

  Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the c-yclohexylmethyl group occupying the SI pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.

  DOI：

  10.1021/ml200137x
• 作为产物：
  描述：

  3-(3-氯苯甲酰基)哌啶-1-羧酸-(R)-叔丁酯 在 (R)-2-甲基-CBS-恶唑硼烷 、 儿萘酚硼烷 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以43%的产率得到(3R)-3-[(R)-(3-氯苯基)羟基甲基]-1-哌啶羧酸1,1-二甲基乙基酯
  参考文献：
  名称：

  Optimization of orally bioavailable alkyl amine renin inhibitors

  摘要：

  Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC50 of 0.83 nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10 mg/kg resulted in >20 h reduction of blood pressure in a double transgenic rat model of hypertension. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.066

文献信息

• RENIN INHIBITORS
  申请人：Baldwin John J.

  公开号：US20100184805A1

  公开（公告）日：2010-07-22

  Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. The present invention is also directed to pharmaceutical compositions comprising a compound described herein or enantiomers, diastereomers, or salts thereof and a pharmaceutically acceptable carrier or excipient.

  揭示了以下结构式所代表的天冬氨酸蛋白酶抑制剂，以及其药学上可接受的盐。这些化合物可经口给药，并结合到天冬氨酸蛋白酶上以抑制其活性。它们在治疗或改善与天冬氨酸蛋白酶活性有关的疾病方面具有用途。本发明还涉及包括本文所述化合物或其对映体、二对映体或盐以及药学上可接受的载体或赋形剂的制药组合物。
• PROCESS FOR THE ASYMMETRIC REDUCTION OF 3-BENZOYLPIPERIDINES
  申请人：Mitchell Mark B.

  公开号：US20100010228A1

  公开（公告）日：2010-01-14

  Disclosed is a process for the asymmetric preparation of a phenyl(3-piperidinyl)methanol represented by Formula (I): wherein R is an optionally substituted phenyl and E is an amine protecting group.

  本发明公开了一种不对称制备苯基(3-哌啶基)甲醇的方法，其化学式表示为(I)：其中，R是可选取的取代苯基，E是氨基保护基。
• Piperidine derivatives as renin inhibitors
  申请人：Baldwin John J.

  公开号：US20090318501A1

  公开（公告）日：2009-12-24

  The present invention is directed to aspartic protease inhibitors represented by the following structural formula; or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using these aspartic protease inhibitors are also disclosed.

  本发明涉及以下结构式所表示的天冬氨酸蛋白酶抑制剂; 或其药学上可接受的盐。本发明还涉及包括结构式（I）的天冬氨酸蛋白酶抑制剂的制药组合物。本发明还揭示了在需要拮抗一种或多种天冬氨酸蛋白酶的主体中拮抗一种或多种天冬氨酸蛋白酶的方法，以及使用这些天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。
• Piperidine and Morpholine Renin Inhibitors
  申请人：Baldwin John J.

  公开号：US20090264432A1

  公开（公告）日：2009-10-22

  Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds for treating or ameliorating a renin mediated disorder in a subject.

  描述了一些口服的化合物，它们能够结合到肾素并抑制其活性。它们在治疗或改善与肾素活性相关的疾病方面是有用的。同时描述了使用这些化合物治疗或改善受肾素介导的疾病的方法。
• Aspartic Protease Inhibitors
  申请人：Baldwin John J.

  公开号：US20100048636A1

  公开（公告）日：2010-02-25

  The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

  本发明涉及天冬氨酸蛋白酶抑制剂。本发明所述的某些天冬氨酸蛋白酶抑制剂可以用以下结构式或其药学上可接受的盐来表示。本发明还涉及包括所述天冬氨酸蛋白酶抑制剂的药物组合物。本发明还涉及在需要拮抗一种或多种天冬氨酸蛋白酶的主体中的方法，以及使用所述天冬氨酸蛋白酶抑制剂治疗天冬氨酸蛋白酶介导的疾病的方法。